Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1759)	8/8/2003 1:59:23 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 3044

Erik, A guy named Mike assured me that MDCO would exceed $100MM in sales of Angiomax this year and that clear evidence of this would be seen by June. Those figures don't support that revenue number. I am so surprised. Mokey, what happened? Where is the bing? H

To: Icebrg who wrote (1759)	8/12/2003 5:27:42 PM
From: Icebrg	Respond to of 3044

Abbott alliance terminated. [From today's 10Q] 8. Subsequent Event In connection with its June 2003 restructuring plan, the Company has discontinued its efforts in the metabolic disease area. As a result, the Company and Abbott agreed to terminate their alliance covering joint discovery, development and commercialization of certain metabolic disease products on August 8, 2003. In the third quarter of 2003, the Company expects to record approximately $15.0 million to $20.0 million in restructuring charges specifically related to the discontinuation of metabolic research and development, which will include termination benefits and costs associated with the Abbott separation agreement.